Deroy & Devereaux Private Investment Counsel Inc. Sells 1,237 Shares of Agilent Technologies, Inc. $A

Deroy & Devereaux Private Investment Counsel Inc. decreased its holdings in Agilent Technologies, Inc. (NYSE:A) by 0.9% in the second quarter, Holdings Channel reports. The firm owned 137,173 shares of the medical research company’s stock after selling 1,237 shares during the quarter. Deroy & Devereaux Private Investment Counsel Inc.’s holdings in Agilent Technologies were worth $16,188,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of A. Brighton Jones LLC increased its holdings in shares of Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock worth $626,000 after purchasing an additional 270 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Agilent Technologies by 34.6% in the 1st quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company’s stock worth $627,000 after purchasing an additional 1,379 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Agilent Technologies by 86.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 51,363 shares of the medical research company’s stock worth $6,009,000 after purchasing an additional 23,800 shares in the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of Agilent Technologies in the 1st quarter worth $31,000. Finally, Ritholtz Wealth Management increased its holdings in shares of Agilent Technologies by 25.3% in the 1st quarter. Ritholtz Wealth Management now owns 2,953 shares of the medical research company’s stock worth $345,000 after purchasing an additional 596 shares in the last quarter.

Agilent Technologies Stock Performance

NYSE:A opened at $138.12 on Wednesday. The stock has a 50-day simple moving average of $125.97 and a two-hundred day simple moving average of $117.31. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $153.84. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. The firm has a market capitalization of $39.16 billion, a PE ratio of 32.42, a P/E/G ratio of 4.51 and a beta of 1.26.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the previous year, the company posted $1.32 earnings per share. Agilent Technologies’s revenue for the quarter was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 22nd. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 30th. Agilent Technologies’s payout ratio is currently 23.24%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on A shares. Wells Fargo & Company lifted their target price on Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Monday, September 15th. Evercore ISI lifted their price objective on Agilent Technologies from $128.00 to $140.00 and gave the stock an “in-line” rating in a report on Tuesday, October 7th. Rothschild & Co Redburn began coverage on Agilent Technologies in a report on Wednesday, October 8th. They issued a “buy” rating and a $165.00 price objective for the company. JPMorgan Chase & Co. lifted their price objective on Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Finally, TD Cowen lifted their price objective on Agilent Technologies from $150.00 to $162.00 and gave the stock a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Agilent Technologies has a consensus rating of “Moderate Buy” and an average target price of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.